OraSure Technologies, Inc. (NASDAQ:OSUR) crossed MACD Bullish signal line on Friday, June 26, 2020

0
106
Goldene Symbolfiguren auf Finanzzeitung

Bullish OraSure Technologies, Inc. NASDAQ:OSUR Grade : D stock signal line crossed on Friday, June 26, 2020. on Thursday 11th June’s trading session, with a change of 6.71% per share while daily volume of 2,289,112 changed hands which is surge of 1.37%

OraSure Technologies, Inc. NASDAQ:OSUR Grade : D stock OSUR closed up 6.71 percent on Thursday, June 25, 2020, on 1.37 times normal volume.

Earning OraSure Technologies, Inc. NASDAQ:OSUR

OraSure Technologies last announced its earnings data on May 6th, 2020. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.06. The firm had revenue of $31.60 million for the quarter, compared to the consensus estimate of $29.48 million. Its revenue was up 4.9% on a year-over-year basis. OraSure Technologies has generated $0.13 earnings per share over the last year and currently has a price-to-earnings ratio of 54.1. OraSure Technologies has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 4th, 2020 based off prior year’s report dates.

About OraSure Technologies, Inc. NASDAQ:OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV-1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.

Grade : D